• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

5-羟色胺(2C)受体激动剂RO 60 0175在三种焦虑动物模型中的作用。

Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety.

作者信息

Kennett G, Lightowler S, Trail B, Bright F, Bromidge S

机构信息

Neurobehavioural Research, SmithKline Beecham Pharmaceuticals, New frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK.

出版信息

Eur J Pharmacol. 2000 Jan 10;387(2):197-204. doi: 10.1016/s0014-2999(99)00706-2.

DOI:10.1016/s0014-2999(99)00706-2
PMID:10650160
Abstract

There is some controversy as to whether 5-HT(2C) receptor agonists are anxiogenic or anxiolytic. The effects of the novel 5-HT(2C) receptor agonist, (S)-2-chloro-5-fluoro-indol-1-yl)-1-methyl ethylamine fumarate (RO 60 0175), in three models of anxiety were therefore tested. RO 60 0175 was found to induce hypolocomotion in rats at doses greater than 0.5 mg/kg s.c., an effect reversed by the selective 5-HT(2C) receptor antagonist, SB-242084. RO 60 0175 did not elicit anxiolytic-like responses in the social interaction test under high light unfamiliar conditions, but suppressed both time spent in social interaction and locomotion at doses of 1 and 3 mg/kg s.c., suggesting a sedative response. In the Vogel conflict test, RO 60 0175 had no significant action on the number of shocks taken. In the Geller-Seifter test, RO 60 0175 (0.3 and 1 mg/kg s.c.) simultaneously reduced both unpunished and punished lever pressing, a profile consistent with sedation. Finally, RO 60 0175 was tested in a rat social interaction test under low light familiar conditions optimal for the detection of anxiogenic-like responses. At 1 and 3 mg/kg s.c., RO 60 0175 reduced both time spent in social interaction and concurrent locomotion, a profile more consistent with sedation than anxiogenesis. In conclusion, RO 60 0175 induced sedative-like responses via 5-HT(2C) receptor activation, but was neither anxiolytic, nor clearly anxiogenic at the doses tested.

摘要

关于5-羟色胺(5-HT)2C受体激动剂是致焦虑还是抗焦虑存在一些争议。因此,测试了新型5-HT2C受体激动剂富马酸(S)-2-氯-5-氟-吲哚-1-基)-1-甲基乙胺(RO 60 0175)在三种焦虑模型中的作用。发现RO 60 0175在皮下注射剂量大于0.5mg/kg时可诱导大鼠运动减少,该作用可被选择性5-HT2C受体拮抗剂SB-242084逆转。在强光陌生条件下的社交互动测试中,RO 60 0175未引发抗焦虑样反应,但在皮下注射剂量为1和3mg/kg时,既抑制了社交互动时间,也抑制了运动,提示有镇静反应。在Vogel冲突测试中,RO 60 0175对遭受电击的次数无显著作用。在Geller-Seifter测试中,RO 60 0175(皮下注射0.3和1mg/kg)同时减少了未受惩罚和受惩罚的杠杆按压,这一表现与镇静作用一致。最后,在弱光熟悉条件下的大鼠社交互动测试中对RO 60 0175进行了测试,该条件最适合检测致焦虑样反应。在皮下注射剂量为1和3mg/kg时,RO 60 0175减少了社交互动时间和同时发生的运动,这一表现更符合镇静作用而非致焦虑作用。总之,RO 60 0175通过5-HT2C受体激活诱导了镇静样反应,但在所测试的剂量下既不是抗焦虑药,也没有明显的致焦虑作用。

相似文献

1
Effects of RO 60 0175, a 5-HT(2C) receptor agonist, in three animal models of anxiety.5-羟色胺(2C)受体激动剂RO 60 0175在三种焦虑动物模型中的作用。
Eur J Pharmacol. 2000 Jan 10;387(2):197-204. doi: 10.1016/s0014-2999(99)00706-2.
2
Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist.神经内分泌学证据表明富马酸(S)-2-(氯-5-氟-吲哚-1-基)-1-甲基乙胺(Ro 60-0175)并非选择性5-羟色胺(2C)受体激动剂。
J Pharmacol Exp Ther. 2003 Mar;304(3):1209-16. doi: 10.1124/jpet.102.043489.
3
A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats.一种5-羟色胺1A受体激动剂和一种5-羟色胺2c受体拮抗剂可减轻大鼠多次乙醇戒断所致的社交互动缺陷。
Psychopharmacology (Berl). 2003 Jun;167(4):344-52. doi: 10.1007/s00213-003-1425-y. Epub 2003 Apr 4.
4
5-HT2C receptor activation prevents stress-induced enhancement of brain 5-HT turnover and extracellular levels in the mouse brain: modulation by chronic paroxetine treatment.5-HT2C 受体激动剂可预防应激引起的小鼠大脑 5-HT 代谢和细胞外水平的增强:慢性帕罗西汀治疗的调节作用。
J Neurochem. 2010 Oct;115(2):438-49. doi: 10.1111/j.1471-4159.2010.06932.x. Epub 2010 Aug 25.
5
Serotonin 2C receptor agonists and the behavioural satiety sequence in mice.血清素2C受体激动剂与小鼠的行为饱腹感序列
Pharmacol Biochem Behav. 2002 Apr;71(4):691-700. doi: 10.1016/s0091-3057(01)00709-2.
6
Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior.研究5-羟色胺(2C)受体在可卡因及食物维持行为中的作用。
J Pharmacol Exp Ther. 2000 Dec;295(3):1183-91.
7
SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.SB 242084,一种具有选择性且能穿透血脑屏障的5-羟色胺2C受体拮抗剂。
Neuropharmacology. 1997 Apr-May;36(4-5):609-20. doi: 10.1016/s0028-3908(97)00038-5.
8
Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis.新型5-羟色胺(5-HT)2C受体激动剂RO 60-0175的辨别性刺激特性:药理学分析
Neuropharmacology. 1999 Mar;38(3):415-23. doi: 10.1016/s0028-3908(98)00203-2.
9
Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats.血清素5-HT2A和5-HT2C受体配体对大鼠尼古丁辨别刺激效应的影响。
Eur J Pharmacol. 2007 Oct 1;571(2-3):156-65. doi: 10.1016/j.ejphar.2007.05.067. Epub 2007 Jun 13.
10
Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635.急性氟西汀、舍曲林或间氯苯哌嗪治疗所诱导的焦虑样效应,可被5-HT2C受体拮抗剂SB-242084预处理逆转,但不能被5-HT1A受体拮抗剂WAY-100635逆转。
Int J Neuropsychopharmacol. 2001 Dec;4(4):399-408. doi: 10.1017/S1461145701002632.

引用本文的文献

1
Evaluation of the 5-HT receptor drugs RO 60-0175, WAY 161503 and mirtazepine in a preclinical model of comorbidity of depression and cocaine addiction.评估 5-HT 受体药物 RO 60-0175、WAY 161503 和米氮平在抑郁和可卡因成瘾共病的临床前模型中的作用。
Pharmacol Rep. 2023 Feb;75(1):99-118. doi: 10.1007/s43440-022-00428-2. Epub 2022 Nov 14.
2
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function.国际基础和临床药理学联合会。CX. 5-羟色胺受体分类:药理学与功能。
Pharmacol Rev. 2021 Jan;73(1):310-520. doi: 10.1124/pr.118.015552.
3
Effect of coadministration of the GABA agonist baclofen and the 5-HT agonist Ro60-0175 on the expression of amphetamine-induced locomotor sensitization.
巴氯芬(GABA 激动剂)与 5-HT 激动剂 Ro60-0175 联合给药对安非他命诱导的运动敏化表达的影响。
Exp Brain Res. 2019 Jul;237(7):1691-1697. doi: 10.1007/s00221-019-05540-z. Epub 2019 Apr 15.
4
Pharmacological Modulation of 5-HT Receptor Activity Produces Bidirectional Changes in Locomotor Activity, Responding for a Conditioned Reinforcer, and Mesolimbic DA Release in C57BL/6 Mice.5-HT 受体活性的药理学调节在 C57BL/6 小鼠中产生了运动活动、条件性强化物反应和中脑边缘 DA 释放的双向变化。
Neuropsychopharmacology. 2017 Oct;42(11):2178-2187. doi: 10.1038/npp.2017.124. Epub 2017 Jun 13.
5
A short history of the 5-HT receptor: from the choroid plexus to depression, obesity and addiction treatment.5-羟色胺受体简史:从脉络丛到抑郁症、肥胖症及成瘾治疗
Psychopharmacology (Berl). 2017 May;234(9-10):1395-1418. doi: 10.1007/s00213-017-4545-5. Epub 2017 Mar 7.
6
5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence.5-羟色胺2C受体脱敏调节5-羟色胺转运体缺陷小鼠的焦虑:从行为到细胞层面的证据
Int J Neuropsychopharmacol. 2014 Oct 31;18(3):pyu056. doi: 10.1093/ijnp/pyu056.
7
Evidence for a role of 5-HT2C receptors in the motor aspects of performance, but not the efficacy of food reinforcers, in a progressive ratio schedule.在渐进比率程序中,5-羟色胺2C受体在行为表现的运动方面发挥作用的证据,但并非在食物强化物的效力方面。
Psychopharmacology (Berl). 2015 Feb;232(4):699-711. doi: 10.1007/s00213-014-3700-5. Epub 2014 Aug 19.
8
Effect of genetic and pharmacological blockade of GABA receptors on the 5-HT2C receptor function during stress.应激期间GABA受体的基因和药理学阻断对5-HT2C受体功能的影响。
J Neurochem. 2014 Dec;131(5):566-72. doi: 10.1111/jnc.12929. Epub 2014 Sep 4.
9
On the behavioural specificity of hypophagia induced in male rats by mCPP, naltrexone, and their combination.雄性大鼠中 mCPP、纳曲酮及其联合应用诱导的摄食量减少的行为特异性。
Psychopharmacology (Berl). 2014 Feb;231(4):787-800. doi: 10.1007/s00213-013-3295-2. Epub 2013 Oct 11.
10
S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models.S32006,一种新型5-羟色胺2C受体拮抗剂,在啮齿动物模型中显示出广泛的抗抑郁和抗焦虑特性。
Psychopharmacology (Berl). 2008 Sep;199(4):549-68. doi: 10.1007/s00213-008-1177-9. Epub 2008 Jun 4.